Castle Biosciences enters collaboration, license agreement with SciBase
Castle Biosciences (CSTL) announced that it has entered into a collaboration and license agreement with SciBase utilizing SciBase's Electrical Impedance Spectroscopy technology which includes both desktop and point-of-care instruments. The initial goal of the collaboration is to advance the development of a diagnostic test that predicts flares in patients diagnosed with atopic dermatitis. Under the collaboration and license agreement, the companies will jointly explore and develop various clinical indications related to dermatologic diseases. SciBase's initial territory will be the EU, Switzerland, United Arab Emirates, Japan and South Korea, while Castle Biosciences' initial territory will be North America. Assuming development success, SciBase will receive a single-digit royalty percentage on the Castle gross margin as well as a low double-digit percentage mark-up on product sales to Castle. SciBase will also receive a milestone payment of $5M when Castle sales reach $50M annually. While the development agreement calls for sharing of development costs, SciBase will be deferring its clinical development costs for the initial indication of pre-symptomatically predicting flares in patients diagnosed with atopic dermatitis, with reimbursement being made from future royalty and milestone payments.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
3 days ago
- Boston Globe
David H. Murdock, a fierce rags-to-riches corporate raider, dies at 102
He gained a reputation as a relentless and often ruthless turnaround specialist who didn't hesitate to lay off thousands of workers, slash benefits, and make deep cuts in order to reshape and sell a company. He would look for companies with what he deemed 'undervalued assets,' swoop in, make necessary if painful changes, and then sell the entity at a significant profit. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up In his oft-stated quest to build the largest private financial empire in the United States, Mr. Murdock took on powerful unions and dominant corporate chieftains, among them Armand Hammer of Occidental Petroleum, and emerged as one of the richest, most successful corporate investors in the nation. In April, Forbes estimated his fortune at $3.7 billion. Advertisement His lack of formal education and humble beginnings fueled his determined rise to wealth and power. In a 1983 interview with The Wall Street Journal, he said: 'Nobody is satisfied with what he has. We were brought on earth to achieve. As long as we want to achieve, we're alive. If we're satisfied, we're already half dead.' Advertisement Well into his 90s, he continued to achieve, serving as chair and CEO of Dole and its parent company, Castle & Cooke, for several decades. 'I never had a boss in my whole life,' he told The New York Times Magazine in 2011. 'I've totally destroyed anybody's ability to tell me what to do.' It was his purchase in 1985 of Castle & Cooke, a venerable and nearly bankrupt Hawaiian agricultural concern, that fueled his ascent as a corporate takeover artist. Castle & Cooke, which had introduced Hawaiian pineapples to the American mainland, provided him with significant land holdings in Hawaii, including Lanai, the sparsely populated and sixth-largest Hawaiian island, home to a vast pineapple plantation. Over time, he turned Castle & Cooke into a successful real estate developer, separating it from its Dole subsidiary. In 2012, he took in hundreds of millions of dollars by selling Lanai to Oracle CEO Larry Ellison. But it was Dole, which Mr. Murdock rebuilt into one of the world's largest sellers of fruit and vegetables, that exemplified his business prowess. He ran Dole for more than 30 years, piling up enormous profits year after year through its global reach, with world headquarters in Dublin and US headquarters in Charlotte, N.C. His only major setback came in 2015, when a Delaware judge ruled that in taking the company private in 2013, Mr. Murdock and its chief operating officer had fraudulently driven down Dole's stock price so that he could buy the business at a cheaper price. The two men were ordered to reimburse shareholders $148 million. Advertisement Mr. Murdock used Dole's profits in the late 2000s to build a $500 million food research center in Kannapolis, N.C., northeast of Charlotte. Its central mission was to study how plant-based diets might lead to longer lives. Married five times, Mr. Murdock was especially devoted to his German-born third wife, Gabriele Murdock, whom he married in 1967. The couple had two sons, and Mr. Murdock adopted a son from his wife's previous marriage. Nearly 20 years her senior, he was devastated when she received a diagnosis of advanced ovarian cancer in 1983. When she died in 1985 at 43, Mr. Murdock had become convinced that lifestyle and diet had contributed to her cancer, and he became obsessed with finding a healthy and sustainable nutrition regimen for himself and for the world. 'If I had known what I know today, I could have saved my wife's life,' he said in the Times Magazine profile, by Frank Bruni. Beginning in his 60s, Mr. Murdock began a quest to change his diet, eating only fruits and vegetables and occasionally fish, eliminating sugar and dairy. 'He wants to reach 125,' Bruni wrote, 'and sees no reason he can't, provided that he continues eating the way he has for the last quarter-century: with a methodical, messianic correctness that he believes can, and will, ward off major disease and minor ailment alike.' David Howard Murdock was born April 11, 1923, in Kansas City, Mo., the middle child and only son of Merte Floyd Murdock, a traveling salesman, and Ruth Gweneth Murdock, who took in laundry and scrubbed floors to help support the family. When David was very young, his father moved the family to Montgomery Township, Ohio, where the boy, who was dyslexic, struggled in school. His learning disabilities made school nightmarish for him. He was taunted and managed only D's, and at age 14 he quit school, just two months into the 10th grade. He was 17 when his mother died of cancer at 42, a loss that haunted him throughout his life. He began working at a service station pumping gas until he was drafted into the Army in 1943. Advertisement After leaving the military at 22, he landed in Detroit penniless. For a time he lived in a park, sleeping under a bush. With the help of a loan company employee he had met in a Detroit diner, he managed to secure $1,200 in loans to buy the diner. He spruced it up, sold it for a small profit and set out for California. He got as far as Phoenix, where he encountered a young city exploding with an influx of postwar transplants. He began to buy up cheap land and build affordable houses for the new arrivals. 'I was building as fast as I could break ground,' he said in the Times Magazine article. 'Bang, bang, bang: I could hardly get a house finished before it was sold.' In 1968, after 17 profitable years, he set off for Los Angeles, where he continued to build, but this time he took on much larger projects, including office buildings. He began investing large stakes in public companies and eventually bought whole companies rather than just stock. In 1974, he acquired Pacific Holding Co. after leading a group of dissident shareholders in a takeover. He took the company private in 1978. That same year, he acquired 19 percent of the shares in Iowa Beef Processor, which he then exchanged for 2.8 percent of the shares in Armand Hammer's Occidental Petroleum, at the time the world's largest independent oil company. Advertisement By 1981, Mr. Murdock had become the largest shareholder of Occidental and began to bang heads with the dynamic Hammer. There was talk that he was angling to succeed Hammer when Hammer retired -- rumors that Mr. Murdock denied. He continued to focus on acquiring stakes in a wide range of companies. Mr. Murdock was not shy about flaunting his wealth. He owned five homes, including a 2,200-acre ranch in Southern California, where he collected longhorn cattle and horses, along with orchids and works of art. He served as co-chair of the Joffrey Ballet Company. At the height of his financial influence, however, Mr. Murdock suffered grievous losses. Less than a year after losing his wife to cancer in 1985, his oldest son, Eugene, 23, drowned in the pool at the family's estate in Beverly Hills. Mr. Murdock's second son, David II, was killed at age 36 in a car crash on the Santa Monica Freeway in 2004. Mr. Murdock leaves his youngest son, Justin, and a granddaughter. This article originally appeared in
Yahoo
3 days ago
- Yahoo
Bulletin from the annual general meeting in SciBase Holding AB (publ)
STOCKHOLM, June 17, 2025 /PRNewswire/ -- Today, the annual general meeting 2025 has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance with the proposals presented in the notice to convene the meeting (which is available on the Company's website ( The annual general meeting resolved: to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2024; that no dividend shall be paid for the financial year 2024 and that the year's result shall be carried forward; to grant the board members and the CEO discharge from liability for the financial year 2024; that the board of directors shall consist of four ordinary members without deputy members and that a registered accounting firm shall be elected as auditor; that the fees payable to the board of directors for the period until the end of the next annual general meeting shall be SEK 404,000 for the chairman of the board and SEK 135,000 to each of the other ordinary board members (who are not employed by a larger shareholder in the Company) and that fees payable to the auditor is to be paid in accordance with approved invoices; for the period until the end of the next annual general meeting, to re-elect Jesper Høiland, Robert Molander and Diana Ferro as board members and to elect Anna Eriksrud as new board member, to re-elect Jesper Høiland as chairman of the board of directors and to elect the auditing firm Öhrlings PricewaterhouseCoopers AB as auditor for the Company, with Magnus Lagerberg as auditor incharge; to adopt principles for the appointment of a nomination committee; to implement an incentive program consisting of a directed issue of warrants and approval of transfer of warrants for the fulfillment of the Company's obligations under the incentive program; to amend the article of association to amend the limits of the Company's share capital and number of shares. Following the amendment, the share capital shall amount to at least SEK 16,914,781.65 and not more than SEK 67,659,126.60 and the number of shares shall be not less than 338,295,633 and not more than 1,353,182,532; and to authorize the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures. Through issuances resolved upon with support from the authorisation - with deviation from the shareholders' preferential rights - the number of shares issued, or number of shares created in connection with exercise of warrants or conversion of convertibles, shall correspond to not more than a 30 per cent dilution of the share capital and the number of shares and votes in the Company after such issue(s). Information regarding the newly elected board members' education, experience, assignments and independence can be found on the Company's website For additional information, please contact:Pia Renaudin, CEOPhone: +46 732 069 802E-mail: Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ)Phone: +46 (0)73 856 42 65E-mail: certifiedadviser@ About SciBase: SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at For press releases and financial reports visit: This information was brought to you by Cision The following files are available for download: SciBase - Bulletin AGM 2025 (ENG) View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30
STOCKHOLM, June 17, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced it has signed a collaboration and license agreement with Castle Biosciences (NASDAQ: CSTL), a US-based leader in molecular diagnostics. The initial goal of the collaboration is to develop a test that predicts flares in patients diagnosed with atopic dermatitis (AD). The method will be based on SciBase's EIS technology and specifically, Nevisense, inclusive of both the desktop and point-of care devices. In connection with the collaboration and license agreement, SciBase intends to carry out a directed share issue of approximately SEK 30 million, of which Castle Biosciences has undertaken to subscribe for shares corresponding to a total amount of approximately SEK 19 million. The subscription price in the directed share issue corresponds to SEK 0.40 per share. Additional information regarding the directed share issue will be announced through a separate press release in connection with this press release. Under the collaboration and license agreement, the Companies will jointly explore and develop various clinical indications related to dermatologic diseases. SciBase's initial territory will be the EU, Switzerland, United Arab Emirates, Japan and South Korea, while Castle Biosciences' initial territory will be North America. Assuming development success, SciBase will receive a single-digit royalty percentage on the Castle gross margin as well as a low double-digit percentage mark-up on product sales to Castle. SciBase will also receive a milestone payment of 5 million U.S. dollars when Castle sales reach 50 million U.S. dollars annually. While the development agreement calls for sharing of development costs, SciBase will be deferring its clinical development costs for the initial indication of pre-symptomatically predicting flares in patients diagnosed with atopic dermatitis, with reimbursement being made from future royalty and milestone payments. "This collaboration with Castle Biosciences is exciting for SciBase," said Pia Renaudin, CEO of SciBase. "It will accelerate the use of Nevisense within the skin barrier health market. It will rapidly broaden our already existing clinical studies pipeline by increasing the number of studies, ultimately speeding up access to more effective therapies for patients with skin barrier dysfunction. We are also pleased to welcome Castle as a shareholder in SciBase." "We are excited to expand our commitment to the dermatologic community, clinicians and patients alike, with the signing of this agreement," said Derek Maetzold, CEO of Castle Biosciences. "Atopic dermatitis is a disease that impacts a significant number of lives, worldwide. We are excited about this opportunity to work with SciBase to develop a test that could improve the management of patients diagnosed with this disease, and potentially other dermatologic diseases. We believe this is a good fit for us, with our existing commercial portfolio of tests in skin cancers, as well as our pipeline test in development for use in patients diagnosed with moderate-to-severe AD who are seeking systemic treatment - the majority of which are managed by the same dermatological clinician." In connection with the collaboration and license agreement, SciBase intends to carry out a directed share issue of approximately SEK 30 million. The subscription price in the directed share issue corresponds to SEK 0.40 per share. Castle Biosciences has undertaken to subscribe for 47,886,950 shares in the directed share issue, corresponding to approximately SEK 19 million. Through the directed share issue, Castle Biosciences is becoming one of SciBase's largest shareholders. Additional information regarding the directed share issue will be announced through a separate press release in connection with this press release and will be available at: About Skin Barrier Dysfunction Skin barrier dysfunction is a key contributing factor to a wide range of skin disorders - including atopic dermatitis, psoriasis, ichthyosis, rosacea, and even acne. Estimates suggest that over 500 million people globally are affected by conditions in which skin barrier impairment plays a central role. Estimated global prevalence by condition includes: Atopic dermatitis (eczema): ~223 million1) Psoriasis: ~125 million2) Rosacea: ~400 million (many with impaired barrier function)3) Additionally, a wide range of cosmetic and subclinical skin concerns-such as dryness, irritation, and product sensitivity-are linked to mild or temporary skin barrier disruption. These milder forms may affect over a billion people globally at some point in their lives. This information is information that SciBase Holding AB is obliged to make public pursuantto the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 22.30 CEST on June 16, 2025. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. For further information please contact: Pia Renaudin, CEO,Phone. +46732069802E-mail: Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ)Tel: +46 (0)73 856 42 65E-mail: certifiedadviser@ About SciBase and NevisenseSciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at For press releases and financial reports visit: -------------------------------------------------------------------------------------- 1Global Report on Atopic Dermatitis - 2https:// 3https:// This information was brought to you by Cision The following files are available for download: SciBase PR - collaboration - final Nevisense Go Nevisense new software 2025 with curve EU View original content:
